JAZZ

Jazz Pharmaceuticals, Inc.

206.78

USD

+1.08

+0.53%

Oct 27, 15:59 UTC -4

Closed

After-Market

206.82

+0.04

+0.02%

Jazz Pharmaceuticals, Inc. (JAZZ) Earnings

JAZZ Earnings Reports

Positive Surprise Ratio

JAZZ beat 23 of 43 last estimates.

53%

Next Report

Next Week

Date of Next Report

Nov 02, 2026

Estimate for Q3 26 (Revenue/ EPS)

$1.23B

-$4.01

Implied change from Q2 26 (Revenue/ EPS)

+1.82%

-170.23%

Implied change from Q3 25 (Revenue/ EPS)

+9.25%

-149.32%

Jazz Pharmaceuticals, Inc. earnings per share and revenue

On Aug 03, 2026, JAZZ reported earnings of 5.71 USD per share (EPS) for Q2 26, missing the estimate of 6.29 USD, resulting in a -9.35% surprise. Revenue reached 1.21 billion, compared to an expected 1.14 billion, with a 6.20% difference. The market reacted with a +3.99% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 9 analysts forecast an EPS of -4.01 USD, with revenue projected to reach 1.23 billion USD, implying an decrease of -170.23% EPS, and increase of 1.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

argenx SE - ADR

Report Date

Oct 22, 2026 For Q3 26

Estimate

$8.19

Actual

$7.80

Surprise

-4.84%

QIAGEN N.V.

Report Date

Oct 21, 2026 For Q3 26

Estimate

$0.63

Actual

$0.65

Surprise

+2.43%

Repligen Corp

Report Date

Oct 27, 2026 For Q3 26

Estimate

$0.46

Actual

$0.53

Surprise

+12.79%

Nautilus Biotechnolgy, Inc. Common Stock

Report Date

Oct 27, 2026 For Q3 26

Estimate

-$0.14

Actual

-$0.12

Surprise

+15.97%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Oct 26, 2026 For Q3 26

Estimate

-$0.39

Actual

-$0.35

Surprise

+11.79%

Tiziana Life Sciences Ltd. Common Shares

Report Date

Oct 16, 2026 For Q2 26

Estimate

-$0.08

Actual

-$0.10

Surprise

-22.55%

FAQ

What were Jazz Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Jazz Pharmaceuticals, Inc. reported EPS of $5.71, missing estimates by -9.35%, and revenue of $1.21B, 6.2% above expectations.

How did the market react to Jazz Pharmaceuticals, Inc.'s Q2 2026 earnings?

The stock price moved up 3.99%, changed from $251.58 before the earnings release to $261.62 the day after.

When is Jazz Pharmaceuticals, Inc. expected to report next?

The next earning report is scheduled for Nov 02, 2026.

What are the forecasts for Jazz Pharmaceuticals, Inc.'s next earnings report?

Based on 9 analysts, Jazz Pharmaceuticals, Inc. is expected to report EPS of -$4.01 and revenue of $1.23B for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.